CN1812776A - 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法 - Google Patents

抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法 Download PDF

Info

Publication number
CN1812776A
CN1812776A CNA2004800139983A CN200480013998A CN1812776A CN 1812776 A CN1812776 A CN 1812776A CN A2004800139983 A CNA2004800139983 A CN A2004800139983A CN 200480013998 A CN200480013998 A CN 200480013998A CN 1812776 A CN1812776 A CN 1812776A
Authority
CN
China
Prior art keywords
pkd
cells
inhibitor
cardiac
cardiac hypertrophy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800139983A
Other languages
English (en)
Chinese (zh)
Inventor
T·A·麦克金西
E·奥尔森
R·B·维加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moegan Co ltd
The University of Texas System
Original Assignee
Moegan Co ltd
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moegan Co ltd, The University of Texas System filed Critical Moegan Co ltd
Publication of CN1812776A publication Critical patent/CN1812776A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
CNA2004800139983A 2003-05-21 2004-05-19 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法 Pending CN1812776A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47229803P 2003-05-21 2003-05-21
US60/472,298 2003-05-21

Publications (1)

Publication Number Publication Date
CN1812776A true CN1812776A (zh) 2006-08-02

Family

ID=33539040

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800139983A Pending CN1812776A (zh) 2003-05-21 2004-05-19 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法

Country Status (9)

Country Link
US (1) US20050112128A1 (enExample)
EP (1) EP1631268A2 (enExample)
JP (1) JP2007505158A (enExample)
CN (1) CN1812776A (enExample)
AU (1) AU2004249114A1 (enExample)
BR (1) BRPI0410787A (enExample)
CA (1) CA2526423A1 (enExample)
MX (1) MXPA05012619A (enExample)
WO (1) WO2004112763A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104558114A (zh) * 2013-10-21 2015-04-29 中国科学院大连化学物理研究所 花粉中具有ace抑制活性的多肽及其应用
CN104558110A (zh) * 2013-10-21 2015-04-29 中国科学院大连化学物理研究所 具有ace抑制活性的多肽及其在降血压药物中的应用
CN104872685A (zh) * 2014-02-27 2015-09-02 长庚医疗财团法人基隆长庚纪念医院 改善心脏衰竭症状的营养组合物
CN102046813B (zh) * 2008-06-02 2016-02-24 牛津生物动力有限公司 检测远距离染色体相互作用的方法
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CN108379585A (zh) * 2018-04-16 2018-08-10 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途
CN112512546A (zh) * 2018-05-23 2021-03-16 匹兹堡大学联邦系统高等教育 心脏特异性靶向肽(ctp)、其组合物和用途
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005018673A1 (en) * 2003-08-21 2005-03-03 Osaka University Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
US20090111868A1 (en) * 2004-12-02 2009-04-30 Marx Steven O Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
WO2007084857A2 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
EP2004234A2 (en) * 2006-04-06 2008-12-24 Novartis AG Combination of organic compounds
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013074587A1 (en) * 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
US9132174B2 (en) * 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
WO2015082716A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
GB2527364A (en) * 2014-06-20 2015-12-23 Imp Innovations Ltd Treatment
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EA035465B1 (ru) * 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
US10907153B2 (en) 2017-07-06 2021-02-02 Michael S. KAPILOFF Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
WO2020058072A1 (en) * 2018-09-18 2020-03-26 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
CN109321602B (zh) * 2018-10-16 2021-11-30 汉恒生物科技（上海）有限公司 Pkd2重组过表达载体及其构建方法和用途
SG11202112499VA (en) 2019-05-15 2021-12-30 Univ Miami Treatment of heart disease by disruption of the anchoring of pp2a
WO2022235771A1 (en) * 2021-05-04 2022-11-10 Enalare Therapeutics Inc. Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4415723A (en) * 1982-03-19 1983-11-15 General Electric Company Randomly branched aromatic polycarbonate from triphenol
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US6043270A (en) * 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5955501A (en) * 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
FR2685346B1 (fr) * 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
TW215434B (enExample) * 1992-03-07 1993-11-01 Hoechst Ag
US5889136A (en) * 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20030134774A1 (en) * 2001-06-15 2003-07-17 Steinberg Susan F. Methods for inhibiting cardiac disorders
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2003222513A1 (en) * 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
US20030229030A1 (en) * 2002-06-11 2003-12-11 Theoharides Theoharis C. Method of treating interleukin-6-mediated inflammatory diseases
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
AU2003214725A1 (en) * 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102046813B (zh) * 2008-06-02 2016-02-24 牛津生物动力有限公司 检测远距离染色体相互作用的方法
CN104558114A (zh) * 2013-10-21 2015-04-29 中国科学院大连化学物理研究所 花粉中具有ace抑制活性的多肽及其应用
CN104558110A (zh) * 2013-10-21 2015-04-29 中国科学院大连化学物理研究所 具有ace抑制活性的多肽及其在降血压药物中的应用
CN104558110B (zh) * 2013-10-21 2018-06-08 中国科学院大连化学物理研究所 具有ace抑制活性的多肽及其在降血压药物中的应用
CN104558114B (zh) * 2013-10-21 2018-06-08 中国科学院大连化学物理研究所 花粉中具有ace抑制活性的多肽及其应用
CN104872685A (zh) * 2014-02-27 2015-09-02 长庚医疗财团法人基隆长庚纪念医院 改善心脏衰竭症状的营养组合物
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CN108379585A (zh) * 2018-04-16 2018-08-10 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
CN108379585B (zh) * 2018-04-16 2020-10-16 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
CN112512546A (zh) * 2018-05-23 2021-03-16 匹兹堡大学联邦系统高等教育 心脏特异性靶向肽(ctp)、其组合物和用途
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用

Also Published As

Publication number Publication date
WO2004112763A3 (en) 2005-09-09
JP2007505158A (ja) 2007-03-08
EP1631268A2 (en) 2006-03-08
WO2004112763A2 (en) 2004-12-29
BRPI0410787A (pt) 2006-06-20
US20050112128A1 (en) 2005-05-26
MXPA05012619A (es) 2006-02-08
AU2004249114A1 (en) 2004-12-29
CA2526423A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
US20050112128A1 (en) Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure
JP5798165B2 (ja) ベータミオシン重鎖の発現を活性化するマイクロｒｎａの同定
Benigni et al. Disruption of the Ang II type 1 receptor promotes longevity in mice
Murthy et al. Ectodomain shedding of EGFR ligands and TNFR1 dictates hepatocyte apoptosis during fulminant hepatitis in mice
Jin et al. A sphingosine kinase 1 mutation sensitizes the myocardium to ischemia/reperfusion injury
JP2021050218A (ja) チロシンキナーゼ阻害剤を用いる組成物および方法
CN1537167A (zh) 酶切范威尔邦德因子(vWF)的蛋白酶
Su et al. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase
De Velasco et al. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer
CN1671424A (zh) 治疗和预防炎症性疾病的诱饵组合物
US20170298107A1 (en) Use of a small native peptide activator of serca pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload
CN1436241A (zh) 鞘氨醇激酶及其应用
WO2007131113A2 (en) Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury
CN1934256A (zh) 针对滑膜蛋白基因启动子的诱杀核酸
CA2555632A1 (en) Inhibition of protein kinase c-related kinase (prk) as a treatment for cardiac hypertrophy and heart failure
Humphrey et al. Loss of TRB3 alters dynamics of MLK3-JNK signaling and inhibits cytokine-activated pancreatic beta cell death
CN1739788A (zh) Trip－br功能的调节和治疗增殖性紊乱的方法
CN1599622A (zh) 用钙调蛋白激酶ⅱ抑制剂治疗结构性心脏病中的心肌功能障碍
US7160859B2 (en) Mst1 modulation of apoptosis in cardiac tissue and modulators of Mst1 for treatment and prevention of cardiac disease
CN1738624A (zh) 治疗心肌梗死的方法
Quintas-Cardama Experimental non-ATP-competitive therapies for chronic myelogenous leukemia
US20140314788A1 (en) Modulation of histone deacetylases for the treatment of metabolic disease, methods and compositions related thereto
EP1827458A2 (en) Selective inhibition of rock 1 in cardiac therapy
US8124111B2 (en) Immunomodulation by altering sphingosine 1-phosphate lyase (SPL) activity
Quezada Meza PROTEIN KINASE CK2 IN HUMAN DISEASES: TOO MUCH OR TOO LITTLE?

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication